Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 256


Defining prognosis for women with breast cancer and CNS metastases by HER2 status.

Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM.

Ann Oncol. 2008 Jul;19(7):1242-8. doi: 10.1093/annonc/mdn036. Epub 2008 Mar 11.


Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.

Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH.

J Clin Oncol. 2010 Jan 1;28(1):92-8. doi: 10.1200/JCO.2008.19.9844. Epub 2009 Nov 23.


Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.

Leyland-Jones B.

J Clin Oncol. 2009 Nov 1;27(31):5278-86. doi: 10.1200/JCO.2008.19.8481. Epub 2009 Sep 21. Review.


Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.

Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, Lin NU.

Breast. 2013 Aug;22(4):525-31. doi: 10.1016/j.breast.2012.12.006. Epub 2013 Jan 23.


Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.

Montagna E, Cancello G, D'Agostino D, Lauria R, Forestieri V, Esposito A, Silvestro L, Accurso A, De Placido S, De Laurentiis M.

Cancer Chemother Pharmacol. 2009 Jan;63(2):275-80. doi: 10.1007/s00280-008-0737-3. Epub 2008 Apr 1.


Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.

Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P.

Ann Oncol. 2005 Nov;16(11):1772-7. Epub 2005 Sep 8.


Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.

Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA.

Clin Cancer Res. 2011 Jul 15;17(14):4834-43. doi: 10.1158/1078-0432.CCR-10-2962.


Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.

Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CL.

Ann Oncol. 2013 Jun;24(6):1526-33. doi: 10.1093/annonc/mdt036. Epub 2013 Mar 4.


Trastuzumab treatment in patients with breast cancer and metastatic CNS disease.

Pieńkowski T, Zielinski CC.

Ann Oncol. 2010 May;21(5):917-24. doi: 10.1093/annonc/mdp353. Epub 2009 Aug 28. Review.


First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.

Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, Quah C, Yardley D, Rugo HS.

Oncologist. 2013;18(5):501-10. doi: 10.1634/theoncologist.2012-0414. Epub 2013 May 7.


Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.

Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, Miles D, Samant M, Welslau M, Diéras V.

Ann Oncol. 2015 Jan;26(1):113-9. doi: 10.1093/annonc/mdu486. Epub 2014 Oct 29.


Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.

Musolino A, Ciccolallo L, Panebianco M, Fontana E, Zanoni D, Bozzetti C, Michiara M, Silini EM, Ardizzoni A.

Cancer. 2011 May 1;117(9):1837-46. doi: 10.1002/cncr.25771. Epub 2010 Nov 10.


Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E.

Cancer. 2003 Jun 15;97(12):2972-7.


Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer.

Kim MM, Dawood S, Allen P, Sahin AA, Woodward WA, Smith BD, Strom EA, Hunt KK, Meric-Bernstam F, Gonzalez-Angulo AM, Buchholz TA.

Cancer. 2012 Oct 15;118(20):4936-43. doi: 10.1002/cncr.27502. Epub 2012 Apr 17.


Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.

Lipton A, Köstler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J, Paquet A, Sherwood T, Huang W, Bates M; Trastuzumab Response Biomarker Group.

Cancer. 2010 Nov 15;116(22):5168-78. doi: 10.1002/cncr.25430.


Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review.

Dawood S, Gonzalez-Angulo AM, Albarracin C, Yu TK, Hortobagyi GN, Buchholz TA, Woodward WA.

Cancer. 2010 Jul 1;116(13):3084-92. doi: 10.1002/cncr.25115.


EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.

Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, Ludovini V, Minenza E, De Angelis V, Crinò L.

Ann Oncol. 2009 Apr;20(4):648-54. doi: 10.1093/annonc/mdn681. Epub 2009 Feb 2.


Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.

Hammerman A, Greenberg-Dotan S, Feldhamer I, Bitterman H, Yerushalmi R.

PLoS One. 2015 Sep 16;10(9):e0138229. doi: 10.1371/journal.pone.0138229. eCollection 2015.

Supplemental Content

Support Center